Arrowhead Pharmaceuticals Announces Presentations at The International Liver Congress™

Home/Newsroom/

Arrowhead Pharmaceuticals Announces...

PASADENA, Calif.–(BUSINESS WIRE)–

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it

will present clinical data on ARC-520, ARC-521, and ARC-AAT, the

company’s prior generation investigational medicines that were being

studied for the treatment of chronic hepatitis B infection and liver

disease associated with alpha-1 antitrypsin deficiency, at The

International Liver Congress™ 2017 (ILC), the annual meeting of the

European Association for the Study of the Liver (EASL) being held in

Amsterdam, the Netherlands from April 19-23, 2017.

Oral Presentations:

Prolonged RNA interference therapy with ARC-520 Injection in

treatment naïve, HBeAg positive and negative patients with chronic HBV

results in significant reductions of HBs antigen

  • Presentation Reference: PS-045

  • Session: Parallel session: Hepatitis B and D: Emerging treatment

    options

  • Date and Time: April 20, 2017 at 5:30 PM CET

  • Authors: Man-Fung Yuen, et al.

Hepatic targeted RNA interference provides deep and prolonged

knockdown of alpha-1 antitrypsin levels in ZZ patients

  • Presentation Reference: LBO-06

  • Session: Late Breaker session

  • Date and Time: April 22, 2017 at 5:15 PM CET

  • Authors: Alice Turner, et al.

Poster Presentation:

A phase 1 study to evaluate safety and tolerability of escalating

single doses of the HBV RNA interference drug ARC-521 in a healthy

volunteer population

  • Presentation Reference: THU-176

  • Session: Viral hepatitis: Hepatitis B and D – Clinical (therapy, new

    compounds, resistance)

  • Session Date and Time: April 20, 2017 from 8:00 AM to 6:00 PM CET

  • Authors: Edward Gane, et al.

Additional details including presentation abstracts can be found on the

ILC website at https://ilc-congress.eu/.

A copy of presentation materials can be accessed by visiting the Events

section of the Arrowhead website after the presentations conclude.

Arrowhead announced on November 29, 2016 that it had discontinued

development of ARC-520, ARC-521, and ARC-AAT. The company continues to

develop ARO-HBV and ARO-AAT, which are follow on investigational RNAi

therapeutics against chronic hepatitis B infection and alpha-1 liver

disease that utilize the company’s new proprietary subcutaneous delivery

system.

The International Liver Congress is a trademark of the European

Association for the Study of the Liver.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable

diseases by silencing the genes that cause them. Using a broad portfolio

of RNA chemistries and efficient modes of delivery, Arrowhead therapies

trigger the RNA interference mechanism to induce rapid, deep, and

durable knockdown of target genes. RNA interference, or RNAi, is a

mechanism present in living cells that inhibits the expression of a

specific gene, thereby affecting the production of a specific protein.

Arrowhead’s RNAi-based therapeutics leverage this natural pathway of

gene silencing.

For more information, please visit www.arrowheadpharma.com,

or follow us on Twitter @ArrowheadPharma.

To be added to the Company’s email list and receive news directly,

please visit http://ir.arrowheadpharma.com/alerts.cfm.

Safe Harbor Statement under the Private Securities Litigation Reform

Act:

This news release contains forward-looking statements within the

meaning of the “safe harbor” provisions of the Private Securities

Litigation Reform Act of 1995. These statements are based upon our

current expectations and speak only as of the date hereof. Our actual

results may differ materially and adversely from those expressed in any

forward-looking statements as a result of various factors and

uncertainties, including the safety and efficacy of our product

candidates, the duration and impact of regulatory delays in our clinical

programs, our ability to finance our operations, the future success of

our scientific studies, our ability to successfully develop drug

candidates, the timing for starting and completing clinical trials,

rapid technological change in our markets, and the enforcement of our

intellectual property rights. Our most recent Annual Report on Form 10-K

and subsequent Quarterly Reports on Form 10-Q discuss some of the

important risk factors that may affect our business, results of

operations and financial condition. We assume no obligation to update or

revise forward-looking statements to reflect new events or circumstances.

Source: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400
ir@arrowheadpharma.com
or
Investor

Relations:
The Trout Group
Chad Rubin, 646-378-2947
ir@arrowheadpharma.com
or
Media:
Russo

Partners
Rich Allan, 646-942-5588
rich.allan@russopartnersllc.com

Source: Arrowhead Pharmaceuticals, Inc.

News Provided by Acquire Media